References
- Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. Morb Mortal Wkly Rep. 2018;67(3):103–5. doi:10.15585/mmwr.mm6703a5.
- Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, Kotton CN, Dooling KL. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80–84. doi:10.15585/mmwr.mm7103a2.
- Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(4):91–94.
- Su JR. Zoster Vaccine Session: Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix) [Internet]. 2020. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/ZosterVaccine-02-Su-508.pdf
- Nelson JC. Zoster Vaccine Session: Vaccine Safety Datalink (VSD) update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix) [Internet]. 2020. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/ZosterVaccine-03-Nelson-508.pdf
- Goud R, Lufkin B, Duffy J, Whitaker B, Wong H-L, Liao J, et al. Risk of Guillain-Barré syndrome following recombinant zoster vaccine in medicare beneficiaries. JAMA Intern Med [Internet]. 2021;181(12):1623.
- Anderson TC, Leung JW, Harpaz R, Dooling KL. Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010–2018. Hum Vaccin Immunother [Internet]. 2021;1–7. doi:10.1080/21645515.2021.1985890.
- Anderson T. Zoster Vaccine Session : Summary and planned risk-benefit analysis regarding use of RZV in immunocompetent adults Post-licensure Safety Monitoring of RZV [Internet]. 2020. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/ZosterVaccine-05-Anderson-508.pdf
- Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380–88.
- Food and Drug Administration (FDA). Assessment of the risk of Guillain-Barre Syndrome (GBS) following recombinant zoster vaccine (RZV) in Medicare data. [Internet]. 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/24-25/02-Zoster-Vaccines-Forshee.pdf
- Izurieta HS, Wu X, Forshee R, Lu Y, Sung H-M, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure. Clin Infect Dis Internetciab125. 2021 ;73(6):941–48. doi:10.1080/00498254.2020.1737890.
- Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics Internet. 2018;36(7):745–58. doi:10.1007/s40273-018-0672-z.
- Lee G, Carr W, Reingold A, Hunter P, Lee G, Temte J, Campos-Outcalt D, Rubin L, O’-Leary S, Savoy M, et al. Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2018;67(45):1271–72. doi:10.15585/mmwr.mm6745a4.
- Anderson T. Zoster Vaccines Session: summary of the HZ work group’s interpretation of recombinant zoster vaccine safety data [Internet]. 2020. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/24-25/04-Zoster-Vaccines-Anderson.pdf